1. An apparatus comprising:
power characterization logic adapted to characterize a power delivery network to obtain a mathematical function response associated with an inputoutput (IO) interface; and
prediction logic adapted to predict an IO pattern to avoid based on the mathematical function response associated with the IO interface.
2. The apparatus of claim 1, wherein the mathematical function response includes a step function response.
3. The apparatus of claim 1, wherein power characterization logic adapted to characterize a power delivery network to obtain a mathematical function response associated with an inputoutput (IO) interface comprises: step function logic adapted to cause a step function stimuli associated with the IO interface and to determine the step function response responsive to the step function stimuli.
4. The apparatus of claim 3, wherein the step function stimuli is selected from a group consisting of driving all IO data transmitters of the IO interface to a high voltage level, pulling all IO data transmitters of the IO interface to a low logic level; and setting all IO data transmitters of the IO interface to a nominal voltage level.
5. The apparatus of claim 3, wherein the prediction logic adapted to predict an IO pattern to avoid based on the mathematical function response associated with the IO interface comprises:
frequency determination logic adapted to determine a resonant frequency for the IO interface based on the step function response; and
pattern logic adapted to determine the IO pattern to avoid based on the resonant frequency.
6. The apparatus of claim 5, wherein the pattern logic is adapted to determine the IO pattern to avoid based on the resonant frequency comprises: the pattern logic being adapted to determine the IO pattern, when transmitted by the IO interface, causes the resonant frequency.
7. The apparatus of claim 3, wherein the prediction logic adapted to predict an IO pattern to avoid based on the mathematical function response associated with the IO interface comprises:
time logic adapted to determine a time from reaching a minimum voltage to reaching a maximum voltage; and
pattern logic adapted to determine the IO pattern to avoid based on reaching a minimum voltage to reaching a maximum voltage.
8. The apparatus of claim 3, further comprising: scrambler logic adapted to detect the IO pattern and to scramble the IO pattern before the IO interface is to transmit the IO pattern in response to the prediction logic predicting the IO pattern is to be avoided.
9. An apparatus comprising:
step function response logic adapted to determine a step function response associated with an inputoutput (IO) interface;
frequency logic coupled to the step function response logic, the frequency logic being adapted to determine a resonant frequency associated with the step function response;
pattern prediction logic coupled to the frequency logic, the pattern prediction logic being adapted to determine at least one IO pattern associated with the resonant frequency; and
pattern generation logic coupled to the pattern prediction logic, the pattern generation logic being adapted to manipulate the least one IO pattern associated with the resonant frequency in response to detecting the at least one IO pattern is to be transmitted by the IO interface.
10. The apparatus of claim 9, wherein the step function response logic adapted to determine a step function response associated with an IO comprises: stimuli logic adapted to pull the IO interface to a voltage level; and voltage comparison logic coupled to temporal logic adapted to determine an amount of time associated with reaching a maximum voltage from a minimum voltage in response to the IO logic reaching the voltage level.
11. The apparatus of claim 10, wherein the temporal logic comprises a first register adapted to shift in bits at a first logical level until the IO logic reaches the voltage level and to subsequently shift in bits at a second logical level after the IO logic reaches the voltage level; and a second register adapted to shift in a representation of a time that corresponds to each of the bits shifted into the first register, and wherein the temporal logic being adapted to determine an amount of time associated with IO logic reaching the voltage level comprises the temporal logic being adapted to determine a first time associated with reaching a minimum voltage from a first representation of the time held in the second register that corresponds to a first bit that includes a first transition in the first register from the first logical level to the second logical level, determine a second time associated with reaching a maximum voltage from a second representation of the time held in the second register that corresponds to a second bit that includes a second transition in the first register from the first logical level to the second logical level, and determine the amount of time from the difference between the first and second representation of time.
12. The apparatus of claim 10, wherein the frequency logic adapted to determine a resonant frequency associated with the step function response comprises: the frequency logic being adapted to determine the resonant frequency based on the amount of time between the IO voltage reaching a maximum voltage level from a minimum voltage level.
13. The apparatus of claim 12, wherein the frequency logic being adapted to determine the resonant frequency based on the amount of time associated with the IO logic reaching the voltage level comprises: the frequency logic being adapted to implement a mathematical expression including one divided by two multiplied by the amount of time.
14. The apparatus of claim 9, wherein pattern generation logic adapted to manipulate the least one IO pattern associated with the resonant frequency in response to detecting the at least one IO pattern is to be transmitted by the IO interface comprises: the pattern generation logic being adapted to scramble the at least one IO pattern in response to detecting the at least one IO pattern.
15. An apparatus comprising:
an inputoutput (IO) interface including a plurality of IO cells;
step logic adapted to cause a step stimuli associated with the plurality of IO cells;
count logic adapted to determine an amount of time between voltage extremes associated with the IO interface in response to the step stimuli associated with the plurality of IO cells; and
prediction logic adapted to determine an IO pattern to avoid based on the amount of time.
16. The apparatus of claim 15, further comprising voltage comparison logic adapted to determine when the voltage extremes are reached.
17. The apparatus of claim 15, wherein the step stimuli associated with the plurality of IO cells comprises: pulling the plurality of IO cells to an end voltage.
18. The apparatus of claim 17, wherein the amount of time includes a number of cycles between voltage extremes associated with the IO interface.
19. The apparatus of claim 15, wherein the count logic adapted to determine the amount of time comprises: a first storage element adapted to indicate a first point at which the plurality of IO cells reach a first voltage extreme and a second point at which the plurality of IO cells reach a second voltage extreme; and a second storage element adapted to indicate a first time corresponding to the first point and a second time corresponding to the second point, wherein the amount of time includes a difference in time between the second point and the first point.
20. The apparatus of claim 15, wherein the prediction logic adapted to determine an IO pattern to avoid based on the amount of time comprises: frequency logic adapted to determine a resonant frequency based on the amount of time and pattern logic adapted to determine the IO pattern based on the resonant frequency.
21. A method comprising:
determining a pattern associated with a resonant frequency for a power delivery network associated with an interface;
detecting the pattern associated with the resonant frequency is to be transmitted by the interface; and
avoiding transmitting the pattern associated with the resonant frequency with the IO interface in response to detecting the pattern associated with the resonant frequency is to be transmitted by the interface.
22. The method of claim 21, wherein determining the pattern associated with resonant frequency for the power delivery network associated with the interface comprises:
initiating a pull down of the interface to a low logical level;
determining a first time for the interface to reach a minimum voltage level associated with the low-logical level;
determining a second time for the interface to reach a next maximum voltage level associated with the low logical level;
determining an amount of time from the first time to the second time;
determining the resonant frequency based on the amount of time; and
determining the pattern, when transmitted by the interface, generates the resonant frequency for the power network associated with the interface.
23. The method of claim 21, wherein determining the pattern associated with resonant frequency for the power delivery network associated with the interface is performed by a flash comparator.
24. The method of claim 21, further comprising:
determining a plurality of additional patterns are also associated with the resonant frequency for the power delivery network associated with the interface; and
avoiding one of the plurality of additional patterns associated with the resonant frequency with the power delivery network in response to detecting the one of the plurality of additional patterns is to be transmitted by the interface.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound, stereoisomer, tautomer, solvate, oxide, ester, or prodrug of Formula (I) or a pharmaceutically acceptable salt thereof
wherein X is O, S, or S(O);
R1 and R2 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, heteroaryl, and substituted heteroaryl; or R1 and R2 are taken together to form a group selected from heterocyclyl, substituted heterocyclyl, heteroaryl, or substituted heteroaryl;
R3 is selected from the group consisting of hydrogen, halo, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, carbonitrile, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heteroaryl, substituted heteroaryl, heterocyclyl, substituted heterocyclyl, amino, substituted amino, acyl, acylamino, alkoxy, substituted alkoxy, carboxyl, carboxyl ester, substituted sulfonyl, aminosulfonyl, and aminocarbonyl;
each R6 is independently alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, or halo;
n is 0, 1, or 2; and
when X is O, R4 is hydrogen, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl, and R5 is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aminocarbonyl, halo, heteroaryl, substituted heteroaryl, cycloalkyl, or substituted cycloalkyl, or R4 and R5 are taken together to form a group selected from heterocyclyl, substituted heterocyclyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; and
when X is S or S(O), R4 is hydrogen, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl, and R5 is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aminocarbonyl, halo, heteroaryl, substituted heteroaryl, cycloalkyl, or substituted cycloalkyl.
2. A compound of claim 1, wherein X is O.
3. A compound of claim 1, wherein X is S.
4. A compound of claim 1, wherein R2 is hydrogen or methyl.
5. A compound of claim 1, wherein R1 is alkyl substituted with 0, 1, 2, or 3 substituents independently selected from halo, hydroxy, haloalkyl, alkoxy, haloalkoxy, aryloxy, aminocarbonyl, carboxyl ester, carboxyl, and substituted sulfonyl.
6. A compound of claim 1, wherein R1 is LR1a wherein L is a covalent bond, alkylidene, or substituted alkylidene, and R1a selected from cycloalkyl, cycloalkenyl, aryl, heterocyclyl, and heteroaryl, wherein each R1a is substituted or unsubstituted.
7. A compound of claim 6, wherein R1a is selected from phenyl, furan-2-yl, furan-3-yl, tetrahydropyran-2-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclohexenyl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, 2,3-dihydrobenzofuran, 2,3-dihydrobenzob1,4dioxine, 3,4-dihydro-2H-benzob1,4dioxepine, pyrazinyl, pyrrolidinyl, piperidinyl, piperidinone, pyrrolidinone, pyridin-2(1H)-one, morpholino, napthyl, bicyclo3.1.1heptane, bicyclo2.2.1heptane, 1,2,3,4-tetrahydronaphthalene, 2,3-dihydro-1H-indene, and azepan-2-one, wherein each R1a is substituted or unsubstituted.
8. A compound of claim 7, wherein L is a covalent bond.
9. A compound of claim 6, wherein L is alkylidene substituted with 0, 1, 2, or 3 substituents independently selected from alkyl, substituted alkyl, hydroxy, alkoxy, haloalkoxy, aminocarbonyl, carboxyl ester, and carboxyl.
10. A compound of claim 1, wherein R1 is
wherein the dashed lines are saturated bonds or unsaturated bonds;
wherein L is a covalent bond, alkylidene, or substituted alkylidene; and
R10, R11, and R12 are independently selected from the group consisting of hydrogen, halo, hydroxy, alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; or R11 is taken together with R12 to form a group selected from the group consisting of aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, heteroaryl, and substituted heteroaryl.
11. A compound of claim 10, wherein the dashed lines are saturated bonds, thereby forming cyclohexyl group.
12. A compound of claim 10, wherein L is a covalent bond.
13. A compound of claim 10, wherein L is methylene or substituted methylene.
14. A compound of claim 13, wherein L is substituted with alkyl, substituted alkyl, carboxyl, aminocarbonyl, and carboxyl ester.
15. A compound of claim 10, wherein R10, R11, and R12 are independently selected from the group consisting of hydrogen, halo, hydroxyl, alkyl, substituted alkyl, and alkoxy.
16. A compound of claim 10, wherein at least one of R10, R11, and R12 is hydroxy.
17. A compound of claim 10, wherein R11 is taken together with R12 to form aryl or substituted aryl.
18. A compound of claim 1, wherein R1 is alkyl or substituted alkyl.
19. A compound of claim 18, wherein R1 is substituted alkyl, wherein the substituent of R1 is selected from the group consisting of alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, heteroaryl, and substituted heteroaryl.
20. A compound of claim 19, wherein R1 is substituted alkyl, wherein the substituent of R1 is cycloalkyl or substituted cycloalkyl.
21. A compound of claim 1, wherein R1 is selected from the group consisting of cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclyl, substituted heterocyclyl, heteroaryl, and substituted heteroaryl.
22. A compound of claim 21, wherein R1 is selected from the group consisting of cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl.
23. A compound of claim 1, wherein R3 is acylamino or aminocarbonyl.
24. A compound of claim 23, wherein R3 is \u2014C(O)NH-LR3a, wherein L is a covalent bond, alkylidene, or substituted alkylidene, and R3a is selected from the group consisting of alkyl, haloalkyl, amino, acylamino, (carboxyl ester)amino, hydroxy, alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl.
25. A compound of claim 24, wherein R3 is \u2014C(O)NHCH3.
26. A compound of claim 1, wherein R3 is hydrogen, carboxyl, substituted alkyl, carbonitrile, heteroaryl, or substituted heteroaryl.
27. A compound of claim 1, wherein R3 is substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl, substituted heterocyclyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, or substituted cycloalkenyl.
28. A compound of claim 1, wherein R3 is selected from the group consisting of pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, pyrimidin-4-yl, pyrimidin-3-yl, pyrimidin-2-yl, thiazoyl, tetrazolyl, imidazol-1-yl, imidazol-2-yl, imidazol-3-yl, pyrazinyl, phenyl, tetrahydropyridine, 1H-pyrrolo2,3-bpyridine, furanyl, oxazole, oxadiazole, cyclopropyl, cyclohexyl, cyclohexenyl, piperidinyl, morpholino, tetrahydro-1H-benzodimidazole, pyrrolidinyl, piperazinyl, and piperazin-2-one, wherein each R3 is substituted or unsubstituted.
29. A compound of claim 1, wherein R4 is hydrogen.
30. A compound of claim 1, wherein R5 is hydrogen.
31. A compound of claim 1 wherein n is 0, R4 and R5 are hydrogen, and R3 is selected from the group consisting of hydrogen, halo, substituted alkyl, carbonitrile, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl, substituted heterocyclyl, amino, substituted amino, acyl, acylamino, alkoxy, substituted alkoxy, carboxyl, carboxyl ester, substituted sulfonyl, aminosulfonyl, and aminocarbonyl.
32. A compound of claim 1, wherein R4 and R5 are taken together to form an aryl or substituted aryl group.
33. A compound, stereoisomer, tautomer, or solvate of claim 1 having Formula (IIa) or (IIb) or a pharmaceutically acceptable salt thereof:
wherein X is O or S;
the dashed lines are saturated bonds or unsaturated bonds;
L is a covalent bond or is alkylidene or substituted alkylidene;
R10, R11, and R12 are independently selected from the group consisting of hydrogen, halo, hydroxy, alkyl, substituted alkyl alkoxy, substituted alkoxy, amino, substituted amino, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; or R11 is taken together with R12 to form a group selected from the group consisting of aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, heteroaryl, and substituted heteroaryl; and
R3 is selected from the group consisting of hydrogen, halogen, substituted alkyl, carbonitrile, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl, substituted heterocyclyl, amino, substituted amino, acyl, acylamino, alkoxy, substituted alkoxy, carboxyl, carboxyl ester, substituted sulfonyl, aminosulfonyl, and aminocarbonyl.
34. A compound of claim 33, wherein the dashed lines are saturated bonds, thereby forming cyclohexyl group.
35. A compound of claim 33, wherein X is O.
36. A compound of claim 33, wherein X is S.
37. A compound of claim 33, wherein L is a covalent bond.
38. A compound of claim 33, wherein L is methylene or substituted methylene.
39. A compound of claim 33, wherein L is substituted with alkyl, substituted alkyl, carboxyl, aminocarbonyl, or carboxyl ester.
40. A compound of claim 33, wherein R10, R11, and R12 are independently selected from the group consisting of hydrogen, halo, hydroxyl, alkyl, substituted alkyl, and alkoxy.
41. A compound of claim 40, wherein at least one of R10, R11, and R12 is hydroxy.
42. A compound of claim 33, wherein R11 is taken together with R12 to form aryl or substituted aryl.
43. A compound of claim 33, wherein R3 is acylamino or aminocarbonyl.
44. A compound of claim 43, wherein R3 is \u2014C(O)NHCH3.
45. A compound of claim 33, wherein R3 is hydrogen, carboxyl, substituted alkyl, carbonitrile, heteroaryl, or substituted heteroaryl.
46. A compound, stereoisomer, tautomer, or solvate of claim 1 having Formula (IIIa) or a pharmaceutically acceptable salt thereof:
wherein X is O or S;
R1 is alkyl or alkyl substituted with a substituent selected from the group consisting of aryl, cycloalkyl, heterocyclyl, substituted heterocyclyl, heteroaryl, and substituted heteroaryl; and
R3 is selected from the group consisting of hydrogen, halogen, substituted alkyl, carbonitrile, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl, substituted heterocyclyl, amino, substituted amino, acyl, acylamino, alkoxy, substituted alkoxy, carboxyl, carboxyl ester, substituted sulfonyl, aminosulfonyl, and aminocarbonyl.
47. A compound of claim 46, wherein X is O.
48. A compound of claim 46, wherein X is S.
49. A compound of claim 46, wherein R1 is alkyl substituted with cycloalkyl.
50. A compound of claim 46, wherein R3 is acylamino or aminocarbonyl.
51. A compound of claim 50, wherein R3 is \u2014C(O)NHCH3.
52. A compound of claim 46, wherein R3 is hydrogen, carboxyl, substituted alkyl, carbonitrile, heteroaryl, or substituted heteroaryl.
53. A compound, stereoisomer, tautomer, or solvate of claim 1 having Formula (IIIb) or a pharmaceutically acceptable salt thereof:
wherein X is O or S;
R1 is selected from the group consisting of acyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclyl, substituted heterocyclyl, heteroaryl, and substituted heteroaryl; and
R3 is selected from the group consisting of hydrogen, halogen, substituted alkyl, carbonitrile, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl, substituted heterocyclyl, amino, substituted amino, acyl, acylamino, alkoxy, substituted alkoxy, carboxyl, carboxyl ester, substituted sulfonyl, aminosulfonyl, and aminocarbonyl.
54. A compound of claim 53, wherein X is O.
55. A compound of claim 53, wherein X is S.
56. A compound of claim 53, wherein R1 is selected from the group consisting of cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl.
57. A compound of claim 53, wherein R3 is acylamino or aminocarbonyl.
58. A compound of claim 57, wherein R3 is \u2014C(O)NHCH3.
59. A compound of claim 53, wherein R3 is hydrogen, carboxyl, substituted alkyl carbonitrile, heteroaryl, or substituted heteroaryl.
60. A compound, stereoisomer, tautomer, solvate, oxide, ester, or prodrug of Formula (IV) or a pharmaceutically acceptable salt thereof:
wherein X is O or S;
R7 is independently selected from the group consisting of alkoxy, haloalkoxy, halo, and carbonitrile;
p is 0, 1, or 2;
R1 is -LR8 or alkyl substituted with 0, 1, 2, or 3 substituents independently selected from halo, hydroxy, haloalkyl, alkoxy, haloalkoxy, aryloxy, aminocarbonyl, carboxyl ester, carboxy, and substituted sulfonyl;
L is a covalent bond, alkylidene, or substituted alkylidene; and
R8 is selected from the group consisting of cycloalkyl, substituted cycloalkyl, tetrahydropyranyl, morpholino, pyridyl, and when p is O, R8 is optionally 2-methoxyphenyl.
61. A compound of claim 60, wherein X is S.
62. A compound of claim 60, wherein p is 0.
63. A compound, stereoisomer, tautomer, solvate, oxide, ester, or prodrug of Formula (V) or a pharmaceutically acceptable salt thereof:
wherein X is O or S;
R1 is -LR9 or alkyl substituted with 0, 1, 2, or 3 substituents independently selected from halo, hydroxy, haloalkyl, alkoxy, haloalkoxy, aryloxy, aminocarbonyl, carboxyl ester, carboxy, and substituted sulfonyl;
L is a covalent bond, alkylidene, or substituted alkylidene; and
R9 is selected from the group consisting of cycloalkyl, substituted cycloalkyl, tetrahydropyranyl, morpholino, and pyridyl.
64. A compound of claim 63, wherein X is S.
65. A compound of claim 63, wherein L is a covalent bond or is alkylidene.
66. A compound of claim 63, wherein R9 is cyclohexyl or substituted cyclohexyl.
67. A compound of claim 1, 60, or 63 selected from Tables 2, 3, or 4 or a stereoisomer, tautomer, solvate, oxide, ester, prodrug, or pharmaceutically acceptable salt thereof.
68. The compound of claim 2 selected from the group consisting of 4-2-(4-Bromo-phenylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-((R)-1-Phenyl-ethylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2-Morpholin-4-yl-phenylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, (2,3-Dihydro-benzo1,4dioxin-6-yl)-6-(6,7-dimethoxy-quinolin-4-yloxy)-benzooxazol-2-yl-amine, 4-2-(2,3-Dihydro-benzo1,4dioxin-6-ylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(1-Thiazol-2-yl-ethylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-((S)-1-Phenyl-ethylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2-Chloro-benzylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2,4-Dichloro-benzylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(3-Methyl-cyclohexylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2-Methoxy-phenylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2-Ethoxy-phenylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-((1S,2S,3S,5R)-2,6,6-Trimethyl-bicyclo3.1.1hept-3-ylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 6-(6,7-Dimethoxy-quinolin-4-yloxy)-benzooxazol-2-yl-((R)-1-phenyl-ethyl)-amine, 4-{2-((1S,2R,4R)-7,7-Dimethyl-bicyclo2.2.1hept-2-ylmethyl)-amino-benzooxazol-6-yloxy}-pyridine-2-carboxylic acid methylamide, 4-2-(2-Fluoro-benzylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2-Methoxy-benzylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-((R)-1-Naphthalen-1-yl-ethylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-((R)-1-Phenyl-propylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-((S)-1-Naphthalen-2-yl-ethylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(Cyclohexylmethyl-amino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-(2-Cyclobutylamino-benzooxazol-6-yloxy)-pyridine-2-carboxylic acid methylamide, 4-(2-Cyclopentylamino-benzooxazol-6-yloxy)-pyridine-2-carboxylic acid methylamide, 4-(2-Cyclohexylamino-benzooxazol-6-yloxy)-pyridine-2-carboxylic acid methylamide, 4-2-(2-Morpholin-4-ylmethyl-phenylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-(2-Phenylamino-benzooxazol-6-yloxy)-pyridine-2-carboxylic acid methylamide, 4-2-(4-Chloro-benzylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2,4-Dimethoxy-phenylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methyl-amide, N-4-(2-Cyclohexylamino-benzooxazol-6-yloxy)-pyridin-2-yl-acetamide, 4-2-(Tetrahydro-pyran-4-ylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-{2-(R)-1-(2-Methoxy-phenyl)-ethylamino-benzooxazol-6-yloxy}-pyridine-2-carboxylic acid methylamide, N-{4-2-(2-Chloro-benzylamino)-benzooxazol-6-yloxy-pyridin-2-yl}-acetamide, 4-2-(2,5-Difluoro-benzylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, N-{4-2-(Cyclohexylmethyl-amino)-benzooxazol-6-yloxy-pyridin-2-yl}-acetamide, (R)-6-(2-Methylcarbamoyl-pyridin-4-yloxy)-benzooxazol-2-ylamino-phenyl-acetic acid, 4-{2-((R)-Methylcarbamoyl-phenyl-methyl)-amino-benzooxazol-6-yloxy}-pyridine-2-carboxylic acid methylamide, 4-2-((R)-2-Hydroxy-1-phenyl-ethylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, (S)-6-(2-Methylcarbamoyl-pyridin-4-yloxy)-benzooxazol-2-ylamino-phenyl-acetic acid, 4-{2-((S)-Methylcarbamoyl-phenyl-methyl)-amino-benzooxazol-6-yloxy}-pyridine-2-carboxylic acid methylamide, 4-{2-(Pyridin-2-ylmethyl)-amino-benzooxazol-6-yloxy}-pyridine-2-carboxylic acid methyl amide, 4-(2-Benzylamino-benzooxazol-6-yloxy)-pyridine-2-carboxylic acid methylamide, 4-2-(3-Chloro-benzylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-{2-2-(2-Pyrrolidin-1-yl-ethyl)-phenylamino-benzooxazol-6-yloxy}-pyridine-2-carboxylic acid methylamide, 4-{2-2-(2-Piperidin-1-yl-ethyl)-phenylamino-benzooxazol-6-yloxy}-pyridine-2-carboxylic acid methylamide, 4-{2-2-(4-Methyl-imidazol-1-yl)-phenylamino-benzooxazol-6-yloxy}-pyridine-2-carboxylic acid methylamide, 4-2-(2-Oxazol-5-yl-phenylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-{2-2-(2-Methyl-imidazol-1-yl)-phenylamino-benzooxazol-6-yloxy}-pyridine-2-carboxylic acid methylamide, 4-(2-Amino-benzooxazol-6-yloxy)-pyridine-2-carboxylic acid methylamide, 4-(2-Hydroxy-benzooxazol-6-yloxy)-pyridine-2-carboxylic acid methylamide, 4-{2-2-(2-Morpholin-4-yl-ethyl)-phenylamino-benzooxazol-6-yloxy}-pyridine-2-carboxylic acid methylamide, 4-2-((1S,2R)-2-Hydroxy-indan-1-ylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-((1R,2S)-2-Hydroxy-indan-1-ylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-((R)-3-Hydroxy-1-phenyl-propylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-((1S,2S)-2-Hydroxy-cyclohexylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methyl amide, (R)-6-(2-Methylcarbamoyl-pyridin-4-yloxy)-benzooxazol-2-ylamino-phenyl-acetic acid methyl ester, 4-2-((R)-1-Cyclohexyl-ethylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, (S)-6-(2-Methylcarbamoyl-pyridin-4-yloxy)-benzooxazol-2-ylamino-phenyl-acetic acid methyl ester, 4-2-((S)-2-Hydroxy-1-phenyl-ethylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-{2-(Pyridin-4-ylmethyl)-amino-benzooxazol-6-yloxy}-pyridine-2-carboxylic acid methylamide, 4-{2-3-(2-Piperidin-1-yl-ethyl)-phenylamino-benzooxazol-6-yloxy}-pyridine-2-carboxylic acid methylamide, 4-{2-(Pyridin-3-ylmethyl)-amino-benzooxazol-6-yloxy}-pyridine-2-carboxylic acid methylamide, 4-2-(Cyclohexylmethyl-amino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid, 4-(2-Phenethylamino-benzooxazol-6-yloxy)-pyridine-2-carboxylic acid methylamide, 4-{2-((R)-Cyclohexyl-methylcarbamoyl-methyl)-amino-benzooxazol-6-yloxy}-pyridine-2-carboxylic acid methylamide, 4-2-(2-Pyrrolidin-1-yl-ethylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2-Piperidin-1-yl-ethylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-{2-(2,3-Dihydro-benzo1,4dioxin-5-ylmethyl)-amino-benzooxazol-6-yloxy}-pyridine-2-carboxylic acid methylamide, 4-2-((S)-1-Cyclohexyl-2-hydroxy-ethylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-((R)-1-Cyclohexyl-2-hydroxy-ethylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, N\u2032-{4-2-(Cyclohexylmethyl-amino)-benzooxazol-6-yloxy-pyridine-2-carbonyl}-hydrazine carboxylic acid tert-butyl ester, 4-2-(Cyclohexylmethyl-amino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid amide, 4-2-(Cyclohex-3-enylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2,4-Difluoro-benzylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2-Bromo-benzylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2-Fluoro-5-methoxy-benzylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-{2-3-(2-Morpholin-4-yl-ethyl)-phenylamino-benzooxazol-6-yloxy}-pyridine-2-carboxylic acid methylamide, 1-{6-(2-Methylcarbamoyl-pyridin-4-yloxy)-benzooxazol-2-ylamino-methyl}-cyclohexanecarboxylic acid ethyl ester, 4-2-(2,6-Dichloro-benzylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2,3-Dichloro-benzylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2-Chloro-6-fluoro-benzylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2,3-Difluoro-benzylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, {4-2-(Cyclohexylmethyl-amino)-benzooxazol-6-yloxy-pyridin-2-yl}-methanol, Cyclohexylmethyl-6-(2-1,3,4oxadiazol-2-yl-pyridin-4-yloxy)-benzooxazol-2-yl-amine, 4-2-(Cyclohexylmethyl-amino)-benzooxazol-6-yloxy-pyridine-2-carbonitrile, 4-2-(2,5-Dimethoxy-benzylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2,6-Dimethoxy-benzyl-amino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2-Dimethylamino-benzylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2-Amino-benzylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2,6-Difluoro-benzylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2-Morpholin-4-yl-benzylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2-Methyl-benzylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(3,4-Dimethoxy-benzylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2,3-Dimethoxy-benzylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2,4-Dimethoxy-benzylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 1-{6-(2-Methylcarbamoyl-pyridin-4-yloxy)-benzooxazol-2-ylamino-methyl}-cyclohexanecarboxylic acid, 4-2-(2,3-Dihydro-benzo1,4dioxin-5-ylamino)-benzo-oxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(Benzo1,3dioxol-5-ylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2-Ethoxy-benzylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2-Trifluoromethyl-benzyl-amino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methyl amide, 4-(2-Isopropylamino-benzooxazol-6-yloxy)-pyridine-2-carboxylic acid methylamide, 4-(2-Isobutylamino-benzooxazol-6-yloxy)-pyridine-2-carboxylic acid methylamide, 4-(2-tert-Butylamino-benzo-oxazol-6-yloxy)-pyridine-2-carboxylic acid methylamide, 4-2-(Cycloheptylmethyl-amino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-{2-(Tetrahydro-furan-2-yl-methyl)-amino-benzooxazol-6-yloxy}-pyridine-2-carboxylic acid methylamide, 4-2-(1-Benzyl-piperidin-4-ylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(1,2,3,4-Tetrahydro-naphthalen-1-ylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2-Pyrazol-1-yl-benzylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(Benzyl-methyl-amino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(1-Phenyl-piperidin-4-ylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-{2-(3,4-Dihydro-2H-benzob1,4dioxepin-6-ylmethyl)-amino-benzooxazol-6-yloxy}-pyridine-2-carboxylic acid methylamide, Cyclohexylmethyl-{6-2-(5-methyl-1H-imidazol-2-yl)-pyridin-4-yloxy-benzooxazol-2-yl}-amine, 4-{2-(2,3-Dihydro-benzo1,4dioxine-5-carbonyl)-amino-benzooxazol-6-yloxy}-pyridine-2-carboxylic acid methylamide, 6-(2-Aminomethyl-pyridin-4-yloxy)-benzooxazol-2-yl-cyclohexylmethyl-amine, 4-{2-(1-Methylcarbamoyl-cyclohexylmethyl)-amino-benzooxazol-6-yloxy}-pyridine-2-carboxylic acid methylamide, 4-2-(2,4,6-Trimethoxy-benzylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(5-Chloro-2-methoxy-benzylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(5-Fluoro-2-methoxy-benzylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2-Fluoro-6-methoxy-benzylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2-Chloro-3,4-dimethoxy-benzylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2-Piperidin-1-yl-benzylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-{2-(2,3-Dihydro-benzo1,4dioxin-2-ylmethyl)-amino-benzooxazol-6-yloxy}-pyridine-2-carboxylic acid methylamide, 4-{2-(4-Benzyl-morpholin-2-ylmethyl)-amino-benzooxazol-6-yloxy}-pyridine-2-carboxylic acid methylamide, 4-2-(2-Chloro-6-methoxy-benzylamino)-benzooxazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-{2-(2,3-Dihydro-benzo1,4dioxin-6-ylmethyl)-amino-benzooxazol-6-yloxy}-pyridine-2-carboxylic acid methylamide, 4-{2-2-(2,3-Dihydro-benzo1,4dioxin-5-yl)-ethylamino-benzooxazol-6-yloxy}-pyridine-2-carboxylic acid methylamide, 4-{2-(2,3-Dihydro-benzofuran-5-ylmethyl)-amino-benzooxazol-6-yloxy}-pyridine-2-carboxylic acid methylamide, and 4-{2-1-(2,3-Dihydro-benzo1,4dioxin-5-yl)-ethylamino-benzooxazol-6-yloxy}-pyridine-2-carboxylic acid methylamide;
or a pharmaceutically acceptable salt, tautomer, solvate, or stereoisomer thereof.
69. The compound of claim 3 selected from the group consisting of 4-2-(4-Chloro-3-trifluoromethyl-phenylamino)-benzothiazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2-Chloro-benzylamino)-benzothiazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(Cyclohexylmethyl-amino)-benzothiazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-{2-(R)-1-(2-Methoxy-phenyl)-ethylamino-benzothiazol-6-yloxy}-pyridine-2-carboxylic acid methylamide, 4-2-(2,4-Dichloro-benzylamino)-benzothiazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-((R)-1-Phenyl-ethylamino)-benzothiazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2-Methoxy-benzylamino)-benzothiazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-(2-Phenethylamino-benzothiazol-6-yloxy)-pyridine-2-carboxylic acid methylamide, 4-2-(2,3-Dichloro-benzylamino)-benzothiazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-(2-Cyclohexylamino-benzothiazol-6-yloxy)-pyridine-2-carboxylic acid methylamide, 4-2-(3-Methyl-cyclohexylamino)-benzothiazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-((1S,2S)-2-Hydroxy-cyclohexylamino)-benzothiazol-6-yl-oxy-pyridine-2-carboxylic acid methylamide, 4-2-((R)-1-Cyclohexyl-ethylamino)-benzothiazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2,5-Difluoro-benzylamino)-benzothiazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2-Fluoro-benzylamino)-benzothiazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-{2-(Tetrahydro-pyran-4-yl-methyl)-amino-benzothiazol-6-yloxy}-pyridine-2-carboxylic acid methylamide, 4-2-(2-Morpholin-4-yl-benzylamino)-benzothiazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2-Pyrazol-1-yl-benzylamino)-benzothiazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2-Dimethylamino-benzylamino)-benzothiazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2,6-Dimethoxy-benzylamino)-benzothiazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2,5-Dimethoxy-benzylamino)-benzothiazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2,3-Difluoro-benzylamino)-benzothiazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(Cycloheptylmethyl-amino)-benzothiazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2,6-Difluoro-benzylamino)-benzothiazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-{2-(Pyridin-2-ylmethyl)-amino-benzothiazol-6-yloxy}-pyridine-2-carboxylic acid methylamide, 4-2-(3,4-Dimethoxy-benzyl-amino)-benzothiazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-{2-(2,3-Dihydro-benzo1,4dioxin-5-ylmethyl)-amino-benzothiazol-6-yloxy}-pyridine-2-carboxylic acid methylamide, 4-2-(2-Piperidin-1-yl-benzylamino)-benzothiazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-{2-(Pyridin-3-ylmethyl)-amino-benzothiazol-6-yloxy}-pyridine-2-carboxylic acid methylamide, 4-2-((1R,2R)-2-Benzyloxy-cyclohexylamino)-benzothiazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-((1S,2S)-2-Benzyloxy-cyclohexylamino)-benzothiazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-((1R,2R)-2-Hydroxy-cyclohexylamino)-benzothiazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-2-(2,6-Dichloro-benzylamino)-benzothiazol-6-yloxy-pyridine-2-carboxylic acid methylamide, 4-(2-(cyclohexylmethylamino)benzothiazol-6-yloxy)-N-(2-methoxyethyl)pyridine-2-carboxamide, 4-(2-(cyclohexylmethylamino)benzothiazol-6-yloxy)-N-(2-(dimethylamino)ethyl)pyridine-2-carboxamide, and 4-2-(4-Sulfonamido-benzylamino)-benzothiazol-6-yloxy-pyridine-2-carboxylic acid methylamide;
or a stereoisomer, tautomer, or solvate thereof or pharmaceutically acceptable salt thereof.
70. A pharmaceutical composition comprising an effective amount of a compound, stereoisomer, tautomer, solvate, oxide, ester, or prodrug or pharmaceutically acceptable salt thereof of any one of claims 1, 60, or 63 and a pharmaceutically acceptable carrier.
71. A composition of claim 70, wherein said compound exhibits an IC50 value with respect to CSF-1R inhibition of less than 1 \u03bcM.
72. A composition of claim 70, further comprising an additional agent.
73. A composition of claim 72, wherein said additional agent is a bisphosphonate.
74. A compound of any one of claims 1, 60, or 63 wherein said compound preferentially inhibits CSF-1R over Raf kinase.
75. A compound of claim 74, wherein said compound inhibits CSF-1R at greater than about 5-fold the activity with respect to IC50 values than in Raf kinase.
76. A compound of claim 74, wherein said compound inhibits CSF-1R at greater than about 10-fold, about 20-fold, about 30-fold, or about 50-fold the activity with respect to IC50 values than in Raf kinase.
77. A compound of claim 74, wherein said compound inhibits CSF-1R at greater than about 100-fold, about 250-fold, about 500-fold, about 750-fold, about 1000-fold, or about 2000-fold the activity with respect to IC50 values than in Raf kinase.
78. A compound of claim 74, wherein said compound inhibits Raf kinase at greater than 1 \u03bcM.
79. A method of treating a CSF-1R mediated disorder in a human or animal subject, comprising administering to the human or animal subject a composition comprising an amount of a compound of any one of claims 1, 60 and 63 effective to inhibit CSF-1R activity in the human or animal subject.
80. A method of claim 79, wherein said compound selectively inhibits CSF-1R.
81. A method of claim 79, wherein the CSF-1R mediated disorder is selected from the group consisting of cancer, osteoporosis, arthritis, atherosclerosis and chronic glomerular nephritis.
82. A method of claim 79, wherein the CSF-1R mediated disorder is a cancer selected from the group consisting of myelocytic leukemia, idiopathic myelofibrosis, breast cancer, cervical cancer, ovarian cancer, endometrial cancer, prostate cancer, hepatocellular cancer, multiple myeloma, lung cancer, renal cancer, and bone cancer.
83. A method of claim 79, wherein the CSF-1R mediated disorder is rheumatoid arthritis.
84. A method of claim 79, wherein the composition further comprises at least one additional agent for treating the CSF-1R mediated disorder.
85. A method of inhibiting CSF-1R comprising contacting a cell with a compound of any one of claims 1, 60, or 63.